BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:Michael Curran\, Ph.D. Immunotherapy November 3\, 2016 Dr. Cur ran joined The University of Texas MD Anderson Cancer Center in 2012 as a ssistant professor of Immunology. In 2014\, he was named scientific direc tor of the Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform\, which coordinates development and production of clinic al immunotherapeutic antibodies based on novel targets and preclinical re agents originating at MD Anderson. Dr. Curran completed B.A. degrees in b iology and foreign affairs and a minor in computer science at the Univers ity of Virginia in 1995\, while receiving accolades for the best undergra duate laboratory research project. He went on to receive a Ph.D. in immun ology from Stanford University in 2001\, where he was awarded the McDevit t prize for the best graduate thesis in his year. Dr. Curran was the firs t recipient of the prestigious American Cancer Society Levy Fellowship to fund his postdoctoral studies in the lab of James P. Allison\, Ph.D. Whi le pursuing his postdoctoral studies at Memorial Sloan-Kettering Cancer C enter\, Dr. Curran published several influential papers describing how T- cell co-stimulatory pathways could be modulated in tandem to mediate immu nologic rejection of melanomas in mice. He detailed how combination block ade of the T-cell co-inhibitory receptors CTLA-4 and PD-1 promoted the re jection of a majority of murine melanomas. This work supported the launch of a series of clinical trials in which more than 50 percent of metastat ic melanoma patients experienced clinical responses and more than 90 perc ent survived beyond two years — an unprecedented result that prompted the Food and Drug Administration to make this the first approved immunothera py antibody combination. In addition\, his subsequent immunologic studies of 4-1BB agonist antibodies earned him the Society for the Immunotherapy of Cancer’s prestigious Presidential Award. In addition to his work on O RBIT\, Dr. Curran has established an independent lab at MD Anderson\, whe re his group studies the origins of the immunosuppressive tumor microenvi ronment and how it can be disrupted to facilitate immune-mediated tumor r ejection. DTEND:20161103T180000Z DTSTAMP:20240328T143904Z DTSTART:20161103T163000Z LOCATION:Houston City Club SEQUENCE:1 SUMMARY:Dr. Michael Curren-M.D.Anderson-Immunotherapy UID:2b852b78-4401-4212-888a-7a292b064f7e X-ALT-DESC:
Michael Curran\, Ph.D.< /strong>
\n\nImmunotherapy
\n\nNovember 3\, 2016
\n\n
\nDr. Curran joined
The University of Texas MD Anderson Cancer Center in 2012 as assistant pr
ofessor of Immunology. In 2014\, he was named scientific director of the
Oncology Research for Biologics and Immunotherapy Translation (ORBIT) pla
tform\, which coordinates development and production of clinical immunoth
erapeutic antibodies based on novel targets and preclinical reagents orig
inating at MD Anderson.
Dr. Curra n completed B.A. degrees in biology and foreign affairs and a minor in co mputer science at the University of Virginia in 1995\, while receiving ac colades for the best undergraduate laboratory research project. He went o n to receive a Ph.D. in immunology from Stanford University in 2001\, whe re he was awarded the McDevitt prize for the best graduate thesis in his year. Dr. Curran was the first recipient of the prestigious American Canc er Society Levy Fellowship to fund his postdoctoral studies in the lab of James P. Allison\, Ph.D.
\n\nWhile p ursuing his postdoctoral studies at Memorial Sloan-Kettering Cancer Cente r\, Dr. Curran published several influential papers describing how T-cell co-stimulatory pathways could be modulated in tandem to mediate immunolo gic rejection of melanomas in mice. He detailed how combination blockade of the T-cell co-inhibitory receptors CTLA-4 and PD-1 promoted the reject ion of a majority of murine melanomas. This work supported the launch of a series of clinical trials in which more than 50 percent of metastatic m elanoma patients experienced clinical responses and more than 90 \;pe rcent survived beyond two years &mdash\; an unprecedented result that pro mpted the Food and Drug Administration to make this the first approved im munotherapy antibody combination. In addition\, his subsequent immunologi c studies of 4-1BB agonist antibodies earned him the Society for the Immu notherapy of Cancer&rsquo\;s prestigious Presidential Award.
\n\nIn addition to his work on ORBIT\, Dr. Curran has established an independent lab at MD \;Anderson\, where his grou p studies the origins of the immunosuppressive tumor microenvironment and how it can be disrupted to facilitate immune-mediated tumor rejection. p>\n END:VEVENT END:VCALENDAR